Расширение использования внутриматочной системы "Мирена": критерии приемлемости ВОЗ

1. Cramer DW et al. Tubal infertility and the intrauterine device. New England J Med 1985; 312: 941–7.
2. Daling JR et al. Primary tubal infertility in relation to the use of an intrauterine device. New England J Med 1985; 312: 937–41.
3. Daling JR et al. The intrauterine device and primary tubal infertility. New England J Med 1992; 326: 203–4.
4. Delbarge W et al. Return to fertility in nulliparous and parous women after removal of the GyneFix intrauterine contraceptive system. Eur J Contracept Reprod Health Care 2002; 7: 24–30.
5. Doll H, Vessey M, Painter R. Return of fertility in nulliparous women after discontinuation of the intrauterine device: comparison with women discontinuing other methods of contraception. BJOG. Int J Obstet Gynaecol 2001; 108: 304–14.
6. Hubacher D et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. New England J Med 2001; 345: 561–7.
7. Skjeldestad FE, Bratt H. Return of fertility after use of IUDs (Nova-T, MLCu250 and MLCu375). Adv Contracept 1987; 3: 139–45.
8. Urbach DR et al. Association of perforation of the appendix with female tubal infertility. Am J Epidemiol 2001; 153: 566–71.
9. Wilson JC. A prospective New Zealand study of fertility after removal of copper intrauterine contraceptive devices for conception and because of complications: a four-year study. Am J Obstet & Gynecol 1989; 160: 391–6.
10. Brenner PF. A clinical trial of the Delta-T intrauterine device: immediate postpartum insertion. Contraception 1983; 28: 135–47.
11. Chi IC, Wilkens L, Rogers S. Expulsions in immediate postpartum insertions of Lippes Loop D and Copper T IUDs and their counterpart Delta devices--an epidemiological analysis. Contraception 1985; 32: 119–34.
12. El-Shafei M. Postpartum and postabortion intrauterine device insertion unmet needs of safe reproductive health: three year experience of Mansoura University Hospital. Eur J Contracept Reprod Health Care 2000; 26: 253–62.
13. Grimes D et al. Immediate post-partum insertion of intrauterine devices.[update of Cochrane Datab System Rev, 2001, CD003036; PMID: 11406064]. [Review] [30 refs]. Cochrane Datab System Rev 2003; CD003036.
14. Morrison C et al. Clinical outcomes of two early postpartum IUD insertion programs in Africa. Contraception 1996; 53: 17–21.
15. Thiery M et al. The ML Cu250; clinical experience in Belgium and The Netherlands. Brit J Obstet Gynaecol 1982; 89: 51–3.
16. Thiery M, Delbeke L, Van Kets H. Comparative performance of two copper-wired IUDs (ML Cu 250 and T Cu 200): immediate postpartum and interval insertion. Adv Contracept Deliv Syst 1980; 1: 27–35.
17. The World Health Organization’s Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Intrauterine Devices for Fertility Regulation. The Alza T IPCS 52, a longer acting progesterone IUD: safety and efficacy compared to the TCu22OC and multiload 250 in two randomized multicentre trials. Clin Reprod Fertil 1983; 2: 113–28.
18. The World Health Organization’s Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Intrauterine Devices for Fertility Regulation. IUD insertion following termination of pregnancy: a clinical trial of the TCu 220C, Lippes loop D, and copper 7. Stud Family Plan 1983; 14: 99–108.
19. The World Health Organization’s Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Intrauterine Devices for Fertility Regulation. IUD insertion following spontaneous abortion: a clinical trial of the TCu 220C, Lippes loop D, and copper 7. Stud Fam Plan 1983; 14: 109–14.
20. El Tagy A et al. Safety and acceptability of post-abortal IUD insertion and the importance of counseling. Contraception 2003; 67: 229–34.
21. Gillett PG et al. A comparison of the efficacy and acceptability of the Copper-7 intrauterine device following immediate or delayed insertion after first-trimester therapeutic abortion. Fertil Steril 1980; 34: 121–4.
22. Grimes D, Schulz K, Stanwood N. Immediate postabortal insertion of intrauterine devices.[update of Cochrane Database Syst Rev. 2000;(2):CD001777; PMID: 10796820]. [Review] [28 refs]. Coch Datab System Rev 2002; CD001777.
23. Gupta I, Devi PK. Studies on immediate post-abortion copper "T" device. Ind J Med Res 1975; 63: 736–9.
24. Moussa A. Evaluation of postabortion IUD insertion in Egyptian women. Contraception 2001; 63: 315–7.
25. Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years’ follow-up. Contraception 2003; 68: 31–4.
26. Stanwood NL, Grimes DA, Schulz KF. Insertion of an intrauterine contraceptive device after induced or spontaneous abortion: a review of the evidence. BJOG: Int J Obstet Gynaecol 2001; 108: 1168–73.
27. Suvisaari J, Lahteenmaki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. Contraception 1996; 54: 201–8.
28. Timonen H, Luukkainen T. Immediate postabortion insertion of the copper-T (TCu-200) with eighteen months follow-up. Contraception 1974; 9: 153–60.
29. Tuveng JM, Skjeldestad FE, Iversen T. Postabortal insertion of IUD. Advances in Contraception 1986; 2: 387–92.
30. Zhang PZ. Five years experience with the copper T 200 in Shanghai – 856 cases. Contraception 1980; 22: 561–71.
31. Barrington JW, Arunkalaivanan AS, Abdel-Fattah. Comparison between the levonorgestrel intrauterine system (LNG-IUS) and thermal balloon ablation in the treatment of menorrhagia. Eur J Obstet Gynecol Reprod Biol 2003; 108: 72–4.
32. Hurskainen R et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001; 357: 273–7.
33. Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fertil Steril 2001; 76: 304–9.
34. Lethaby AE, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. Coch Dat System Rev 2000; CD002126.
35. Stewart A et al. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG: Int J Obstet Gynaecol 2001; 108: 74–86.
36. Fedele L et al. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001; 75: 485–8.
37. Vercellini P et al. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil Steril 1999; 72: 505–8.
38. Fedele L et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997; 68: 426–9.
39. Grigorieva V et al. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 2003; 79: 1194–8.
40. Mercorio F et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception 2003; 67: 277–80.
41. Wildemeersch D, Schacht E, Wildemeersch P. Treatment of primary and secondary dysmenorrhea with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care 2001; 6: 192–8.
42. Wildemeersch D, Schacht E. The effect on menstrual blood loss in women with uterine fibroids of a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Obstet Gynecol Reprod Biol 2002; 102: 74–9.
43. Wildemeersch D, Schacht E, Wildemeersch P. Contraception and treatment in the perimenopause with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: an extended pilot study. Contraception 2002; 66: 93–9.
44. Wildemeersch D, Schacht E, Wildemeersch P. Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment in peri and postmenopausal women. Maturitas 2003; 44: 237–45.
45. Larsson B, Wennergren M. Investigation of a copper-intrauterine device (Cu-IUD) for possible effect on frequency and healing of pelvic inflammatory disease. Contraception 1977; 15: 143–9.
46. Soderberg G, Lindgren S. Influence of an intrauterine device on the course of an acute salpingitis. Contraception 1981; 24: 137–43.
47. Teisala K. Removal of an intrauterine device and the treatment of acute pelvic inflammatory disease. Ann Med 1989; 21: 63–5.
48. Faundes A et al. The risk of inadvertent intrauterine device insertion in women carriers of endocervical Chlamydia trachomatis. Contraception 1998; 58: 105–9.
49. Ferraz do Lago R et al. Follow-up of users of intrauterine device with and without bacterial vaginosis and other cervicovaginal infections. Contraception 2003; 68: 105–9.
50. Morrison CS et al. Use of sexually transmitted disease risk assessment algorithms for selection of intrauterine device candidates. Contraception 1999; 59: 97–106.
51. Pap-Akeson M et al. Genital tract infections associated with the intrauterine contraceptive device can be reduced by inserting the threads into the uterine cavity. Brit J Obstet Gynaecol 1992; 99: 676–9.
52. Sinei SK et al. Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. Brit J Obst Gynaecol 1990; 97: 412–9.
53. Skjeldestad FE et al. IUD users in Norway are at low risk for genital C. trachomatis infection. Contraception 1996; 54: 209–12.
54. Walsh TL et al. IUD Study Group. Effect of prophylactic antibiotics on morbidity associated with IUD insertion: results of a pilot randomized controlled trial. Contraception 1994; 50: 319–27.
55. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ 1992; 304: 809–13.
56. Carael M et al. Human immunodeficiency virus transmission among heterosexual couples in Central Africa. AIDS 1988; 2: 201–5.
57. Kapiga SH et al. Risk factors for HIV infection among women in Dar-es-Salaam, Tanzania. J Acquir Immune Defic Syndr 1994; 7: 301–9.
58. Kapiga SH et al. The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS 1998; 12: 75–84.
59. Mann JM et al. HIV infection and associated risk factors in female prostitutes in Kinshasa, Zaire. AIDS 1988; 2: 249–54.
60. Martin HLJr et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Diseas 1998; 178: 1053–9.
61. Mati JK et al. Contraceptive use and the risk of HIV infection in Nairobi, Kenya. Int J Gynaecol Obstet 1995; 48: 61–7.

И.С.Савельева, Ж.А.Городничева

ФГУ Научный центр акушерства, гинекологии и перинатологии Федерального агентства по высокотехнологичной 
медицинской помощи, Москва